Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells

Cancer Research

Volumn 61, Issue 23, 2001, Pages 8486-8491

  Takei, Yoshifumi ^a   Kadomatsu, Kenji ^a   Muramatsu, Takashi ^a   Matsuo, Seiichi ^a   Itoh, Hiroshi ^b   Nakazawa, Kunihiko ^c   Kubota, Shunichiro ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Koken Bioscience Institute   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTISENSE OLIGODEOXYNUCLEOTIDE; ATELOCOLLAGEN; BROXURIDINE; FIBROBLAST GROWTH FACTOR; LIPOSOME; MESSENGER RNA; MIDKINE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; COLONY FORMATION; CONTROLLED STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECTUM CARCINOMA; RNA STRUCTURE; TUMOR GROWTH; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CARRIER PROTEINS; CELL DIVISION; CYTOKINES; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; RECTAL NEOPLASMS; RNA, MESSENGER; THIONUCLEOTIDES; TRANSFECTION;

EID: 0035577793     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Growth factors and cancer
2. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: Effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts
3. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-I in human melanomas blocks intratumoral angiogenesis and tumor growth
4. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells
5. Reversion of human glioblastoma malignancy by U-small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression
6. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells
7. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo
8. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis
9. Solution structure of midkine, a new heparin-binding growth factor
10. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity
11. Molecular cloning of the 18-kDa growth-associated protein of developing brain
12. A new family of heparin-binding growth differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas
13. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues
14. Midkine and pleiotrophin expression in normal and malignant breast tissue
15. Differential expression of pleiotrophin and midkine in advanced neuroblastomas
16. Increased midkine gene expression in human gastrointestinal cancers
17. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers
18. Midkine induces the transformation of N-H3T3 cells
19. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons
20. Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: Regulation of Bc-2 expression by midkine
21. Purification of recombinant midkine and examination of its biological activities: Functional comparison of new heparin binding factors
22. Midkine (MK), a retinoic acid-inducible growth/differentiation factor: Immunochemical evidence for the function and distribution
23. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: Chemotactic activity to neutrophils and association with inflammatory synovitis
24. A receptor-like protein-tyrosine phosphatase PTP ζ/RPTP β binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTP ζ
25. Neointima formation in a restenosis model is suppressed in midkine-deficient mice
26. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: The minipellet
27. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
28. A retinoic acid-responsive gene MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product
29. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
30. Enzyme-linked immunoassay for midkine and its application to evaluation of midkine levels in developing mouse brain and in sera from patients with hepatocellular carcinomas
31. Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts
32. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
33. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
34. Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information
35. Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose
36. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis
37. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors
38. Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells
39. Serum midkine levels are increased in patients with various types of carcinomas
40. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice
41. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth
42. Melanoma angio-genesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin
43. Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus
44. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3)
45. Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis
46. Involvement of receptor-like protein tyrosine phosphatase ζ/RPTPβ and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration
47. Pleiotrophin signals increased tyrosine phosphorylation of β-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase β/ζ
48. LDL receptor-related protein as a component of the midkine receptor
49. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin
50. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase ζ, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase
51. Signal transduction pathways involved in the mitogenic activity of pleiotrophin. Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways
52. Cortactin-Src kinase signaling pathway is involved in N-syndecan-dependent neurite outgrowth
53. Pleiotrophin and midkine in normal development and tumor biology
54. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides